JBJing Bi

Jing Bi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jing Bi has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • Adong Shen

    Laboratory of Respiratory Diseases, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, Beijing Key Laboratory of Core Technologies for the Prevention and Treatment of Emerging Infectious Diseases in Children, Key Laboratory of Major Diseases in Children, Ministry of Education, National Clinical Research Center for Respiratory Diseases, National Center for Children's Health, Beijing, China

    2 shared publications
  • Tian-Yi Wang

    Baoding Key Laboratory for Precision Diagnosis and Treatment of Infectious Diseases in Children, Hebei Key laboratory of Infectious Diseases Pathogenesis and Precise Diagnosis and Treatment, Baoding Hospital of Beijing Children’s Hospital, Capital Medical University

    2 shared publications
  • Ting-Ting Jiang

    Baoding Key Laboratory for Precision Diagnosis and Treatment of Infectious Diseases in Children, Hebei Key laboratory of Infectious Diseases Pathogenesis and Precise Diagnosis and Treatment, Baoding Hospital of Beijing Children’s Hospital, Capital Medical University

    2 shared publications
  • A-Dong Shen

    Baoding Key Laboratory for Precision Diagnosis and Treatment of Infectious Diseases in Children, Hebei Key laboratory of Infectious Diseases Pathogenesis and Precise Diagnosis and Treatment, Baoding Hospital of Beijing Children’s Hospital, Capital Medical University

    1 shared publication
  • Alexander V. Dmitriev

    Department of Molecular Biotechnology, Saint-Petersburg State Institute of Technology

    1 shared publication
  • Cai-Xia Liu

    Baoding Key Laboratory for Precision Diagnosis and Treatment of Infectious Diseases in Children, Hebei Key laboratory of Infectious Diseases Pathogenesis and Precise Diagnosis and Treatment, Baoding Hospital of Beijing Children’s Hospital, Capital Medical University

    1 shared publication

Latest Publications

  • Open Access

    Etiological characteristics and genotypes of Mycoplasma pneumoniae infection in children in Baoding from 2022 to 2024

    by Ze-Ming Wang, Ting-Ting Jiang, Wei-Wei Jiao, Tian-Yi Wang, Lu Yu, Jing-Jing Chu, Kai-Xuan Cao, Yu-Ping Chen, Cai-Xia Liu, Jie Tan, et al.

    To investigate the epidemiology associated with genetic types and macrolide resistance of Mycoplasma pneumoniae (MP) in children during and post-COVID-19 in Baoding. A retrospective analysis was conducted on 13,534 children and adolescents (≤18 years old) with community-acquired pneumonia from January 2022 to December 2024. MP detection and macrolide resistance-associated mutation analysis were performed using multiplex real-time PCR. Multilocus variable-number tandem-repeat analysis (MLVA) was used for genotyping. Mycoplasma pneumoniae pneumonia (MPP) cases rose significantly from 844 (2022) to 6,346 (2024) ( P < 0.01), while the positive rate remained stable (67.68%–77.72%). Patients aged 5–18 years had the highest positive rate. Severe MPP (SMPP) prevalence declined from 22.75% (2022) to 6.16% (2024) ( P < 0.01), with MP infections peaking in the fourth quarter of 2023–2024 and prevailing year-round in 2024. Macrolide-resistant MP (MRMP) prevalence was 95.92% overall (97.27%/2022, 93.85%/2023, 96.56%/2024), with no significant difference between SMPP and non-severe MPP groups. MLVA-type M3562 decreased from 77.10% to 33.13%, while M4572 increased to 56.72% (2024) as the dominant type. Both genotypes had 99.00%–100.00% macrolide resistance. Notably, SMPP was more common in M3562-infected patients (20.63%) than M4572-infected ones (13.97%, P < 0.01). MP infections re-emerged between 2023 and 2024, with persistently high macrolide resistance. There was a genotype shift from M3562 to M4572. These findings highlight the need for strengthened surveillance, rational antibiotic use, and targeted prevention strategies to address MP infections in the post-pandemic period. IMPORTANCE: Understanding the epidemiological characteristics of Mycoplasma pneumoniae (MP) is essential for effective management of Mycoplasma pneumoniae pneumonia (MPP). This study examines the epidemiology associated with genetic types and macrolide resistance of MP in children with MPP in Baoding, China, during and after the lifting of non-pharmaceutical interventions (NPIs). Data from 9,728 children diagnosed with MPP from January 2022 to December 2024 were analyzed. MPP cases rose significantly from 844 in 2022 to 6,346 in 2024, while the overall prevalence of macrolide-resistant MP was 95.92%. Notably, a striking genotype shift from M3562 (77.10%/2022–33.13%/2024) to M4572 (15.74%/2022–56.72%/2024) was observed over this period. Severe MPP proportion was significantly higher in patients with M3562 (20.63%) infection than that with M4572 (13.97%). This research underscores the urgent need for strengthened surveillance, rational antibiotic use, and targeted prevention strategies to address MP infections in the post-pandemic period.

  • Open Access

    Changing patterns of respiratory pathogens in hospitalized children with community-acquired pneumonia in northern China following the lifting of non-pharmaceutical interventions

    by Ting-Ting Jiang, Ze-Ming Wang, He Tang, Lin Sun, Qian Han, Hui Qi, Tian-Yi Wang, Jing Xiao, Chenxi Li, Xue-Mei Yang, et al.

    An observational, single-center study was conducted among hospitalized children with community-acquired pneumonia in the Baoding area. The objective was to compare the respiratory pathogen profiles and epidemiological patterns during and after the lifting of non-pharmaceutical interventions (NPIs, including mask-wearing, social distancing, lockdowns, etc.). A total of 9,362 hospitalized children diagnosed with CAP in Baoding from January 2022 to December 2023 were included. Both viral and bacterial pathogens were detected by multiplex PCR. The NPIs were lifted in Baoding from 2 December 2022. A comparative analysis was conducted on demographic data, epidemiological data, pathogen detection rates, and co-infection patterns that were compared between the full year 2022 and 2023. The detection rate of at least one pathogen significantly increased from 74.2% (2,925/3,940) in 2022 to 86.5% (4,690/5,422) in 2023 ( P < 0.001). Mycoplasma pneumoniae , Streptococcus pneumoniae , human rhinovirus, respiratory syncytial virus (RSV), and Haemophilus influenzae were the predominant pathogens. Notably, co-infection rates rose from 25.1% (988/3,940) in 2022 to 45.1% (2,445/5,422) in 2023 ( P < 0.001), particularly viral-bacterial co-infections. The positive detection rates for many pathogens among severe pneumonia cases increased. Additionally, an age shift in infection patterns was observed, with older children showing a higher prevalence of RSV. Following the lifting of NPIs, an increase in the detection rates of pathogens was observed, as were fluctuations in the dynamics of viral and bacterial pathogens, underscoring the urgent need to adapt clinical management and public health policies to address emerging infection trends. IMPORTANCE: Community-acquired pneumonia (CAP) remains the leading infectious cause of death in children worldwide. Understanding the pathogens responsible for CAP is essential for effective diagnosis and treatment. This study examines the changes in respiratory pathogens and epidemiological patterns in children with CAP in Baoding, China, before and after the lifting of non-pharmaceutical interventions (NPIs). Data from 9,362 children diagnosed with CAP from January 2022 to December 2023 were analyzed. The detection rate of at least one pathogen increased significantly from 74.2% in 2022 to 86.5% in 2023. Notably, co-infection rates rose from 25.1% to 45.1%, with viral-bacterial co-infections being more common. This research underscores the urgent need to adapt clinical management and public health policies to address the changing infection trends, highlighting their importance and innovation in understanding the impact of NPIs on pediatric respiratory infections.


  • Open Access

    Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children

    by Hanzhao Zhu, Xintong Zhou, Zengfang Zhuang, Lianju Li, Jing Bi, Kaixia Mi

    Tuberculosis (TB) is a major public health problem, with nearly 10 million new cases and millions of deaths each year. Around 10% of these cases are in children, but only a fraction receive proper diagnosis and treatment. The spread of drug-resistant (DR) strain of TB has made it difficult to control, with only 60% of patients responding to treatment. Multi-drug resistant TB (MDR-TB) is often undiagnosed in children due to lack of awareness or under-diagnosis, and the target for children’s DR-TB treatment has only been met in 15% of goals. New medications such as bedaquiline and delamanid have been approved for treating DR-TB. However, due to age and weight differences, adults and children require different dosages. The availability of child-friendly formulations is limited by a lack of clinical data in children. This paper reviews the development history of these drugs, their mechanism of action, efficacy, safety potential problems and current use in treating DR-TB in children.


  • Open Access

    Recombinase Polymerase Amplification Combined with Real-Time Fluorescent Probe for Mycoplasma pneumoniae Detection

    by Tingting Jiang, Yacui Wang, Weiwei Jiao, Yiqin Song, Qing Zhao, Tianyi Wang, Jing Bi, Adong Shen

    Mycoplasma pneumoniae (M. pneumoniae) is one of the major causes of community-acquired pneumonia, accounting for 20–40% of total cases. Rapid and accurate detection of M. pneumoniae is crucial for the diagnosis and rational selection of antibiotics. In this study, we set up a real-time recombinase polymerase amplification (RPA) assay to detect the conserved gene CARDS of M. pneumoniae. The amplification can be finished in 20 min at a wide temperature range from 37–41 °C. The limit of detection of RPA assay was 10 fg per microliter. Cross-reaction with commonly detected respiratory pathogens was not observed using RPA assay. Among clinical sputum samples, the detection rate of RPA assay and real-time PCR assay was 48.4% (92/190) and 46.3% (88/190), respectively (p = 0.68). Therefore, the RPA assay for M. pneumoniae detection is rapid and easy to use and may serve as a promising test for early diagnosis of M. pneumoniae infection.